MX2020004045A - Molecula inhibidora del acido nucleico de la catenina beta. - Google Patents
Molecula inhibidora del acido nucleico de la catenina beta.Info
- Publication number
- MX2020004045A MX2020004045A MX2020004045A MX2020004045A MX2020004045A MX 2020004045 A MX2020004045 A MX 2020004045A MX 2020004045 A MX2020004045 A MX 2020004045A MX 2020004045 A MX2020004045 A MX 2020004045A MX 2020004045 A MX2020004045 A MX 2020004045A
- Authority
- MX
- Mexico
- Prior art keywords
- nucleic acid
- acid inhibitor
- inhibitor molecule
- beta catenin
- catenin nucleic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Optics & Photonics (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Nanotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Abstract
En la presente se proporciona una potente molécula inhibidora del ácido nucleico de la catenina ß optimizada con un patrón particular de nucleótidos modificados; también se proporcionan métodos y composiciones para reducir la expresión de la catenina ß y métodos y composiciones para tratar el cáncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762573999P | 2017-10-18 | 2017-10-18 | |
PCT/US2018/056317 WO2019079472A1 (en) | 2017-10-18 | 2018-10-17 | BETA-CATENIN NUCLEIC ACID INHIBITOR MOLECULE |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020004045A true MX2020004045A (es) | 2020-07-20 |
Family
ID=66173850
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020004045A MX2020004045A (es) | 2017-10-18 | 2018-10-17 | Molecula inhibidora del acido nucleico de la catenina beta. |
Country Status (11)
Country | Link |
---|---|
US (2) | US11008571B2 (es) |
EP (1) | EP3672980A4 (es) |
JP (2) | JP2021500026A (es) |
KR (1) | KR20200078538A (es) |
CN (1) | CN111225922B (es) |
AU (1) | AU2018350983A1 (es) |
BR (1) | BR112020007443A2 (es) |
CA (1) | CA3076924A1 (es) |
IL (1) | IL273772A (es) |
MX (1) | MX2020004045A (es) |
WO (1) | WO2019079472A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023122317A2 (en) * | 2021-12-23 | 2023-06-29 | Aligos Therapeutics, Inc. | SHORT INTERFERING NUCLEIC ACID (SINA) MOLECULES FOR TARGETING β-CATENIN AND USES THEREOF |
WO2023122316A2 (en) * | 2021-12-23 | 2023-06-29 | Aligos Therapeutics, Inc. | SPLICE SWITCH OLIGONUCLEOTIDE (SSO) MOLECULES FOR TARGETING β-CATENIN AND USES THEREOF |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2379083B1 (en) * | 2008-12-18 | 2017-08-16 | Dicerna Pharmaceuticals, Inc. | Extended dicer substrate agents and methods for the specific inhibition of gene expression |
WO2010093788A2 (en) | 2009-02-11 | 2010-08-19 | Dicerna Pharmaceuticals, Inc. | Multiplex dicer substrate rna interference molecules having joining sequences |
EP3587579B1 (en) * | 2010-07-06 | 2021-03-03 | Dicerna Pharmaceuticals, Inc. | Methods and compositions for the specific inhibition of beta-catenin by double-stranded rna |
EP3330377A1 (en) * | 2010-08-02 | 2018-06-06 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina) |
KR20230074615A (ko) * | 2011-11-18 | 2023-05-30 | 알닐람 파마슈티칼스 인코포레이티드 | 변형된 RNAi 제제 |
ES2858403T3 (es) * | 2014-12-15 | 2021-09-30 | Dicerna Pharmaceuticals Inc | Acidos nucleicos de doble hebra modificados por ligando |
WO2017160983A1 (en) * | 2016-03-16 | 2017-09-21 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for the treatment of a beta-catenin-associated disease or disorder |
-
2018
- 2018-10-17 BR BR112020007443-8A patent/BR112020007443A2/pt unknown
- 2018-10-17 AU AU2018350983A patent/AU2018350983A1/en not_active Abandoned
- 2018-10-17 MX MX2020004045A patent/MX2020004045A/es unknown
- 2018-10-17 KR KR1020207013634A patent/KR20200078538A/ko not_active Application Discontinuation
- 2018-10-17 JP JP2020521889A patent/JP2021500026A/ja active Pending
- 2018-10-17 CA CA3076924A patent/CA3076924A1/en active Pending
- 2018-10-17 US US16/754,452 patent/US11008571B2/en active Active
- 2018-10-17 EP EP18867422.0A patent/EP3672980A4/en not_active Withdrawn
- 2018-10-17 CN CN201880067973.3A patent/CN111225922B/zh active Active
- 2018-10-17 WO PCT/US2018/056317 patent/WO2019079472A1/en unknown
-
2020
- 2020-04-02 IL IL273772A patent/IL273772A/en unknown
-
2021
- 2021-04-15 US US17/231,696 patent/US20210238603A1/en not_active Abandoned
-
2023
- 2023-08-17 JP JP2023132823A patent/JP2023175693A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US11008571B2 (en) | 2021-05-18 |
US20200270606A1 (en) | 2020-08-27 |
EP3672980A4 (en) | 2021-06-16 |
BR112020007443A2 (pt) | 2020-10-20 |
JP2021500026A (ja) | 2021-01-07 |
WO2019079472A1 (en) | 2019-04-25 |
CN111225922A (zh) | 2020-06-02 |
CN111225922B (zh) | 2023-07-18 |
JP2023175693A (ja) | 2023-12-12 |
AU2018350983A1 (en) | 2020-04-09 |
US20210238603A1 (en) | 2021-08-05 |
KR20200078538A (ko) | 2020-07-01 |
CA3076924A1 (en) | 2019-04-25 |
EP3672980A1 (en) | 2020-07-01 |
IL273772A (en) | 2020-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020003995A (es) | Nuevas moleculas de acido nucleico artificiales. | |
ZA202102549B (en) | Substituted tolyl as fungicides | |
MX2020004698A (es) | Exosomas que comprenden agentes terapeuticos de arn. | |
CY1122398T1 (el) | Συνδυαστικες θεραπειες με αντισωματα anti-cd38 | |
MX2020004287A (es) | Procesamiento de biomasa. | |
MX2018006148A (es) | Inhibidores de cxcr2. | |
MX2020004095A (es) | Determinacion de localizacion para operacion de vehiculo. | |
EA201891209A1 (ru) | Модуляторы хемокиновых рецепторов | |
MX2020003430A (es) | Derivados de 1-bencil-2-imino-4-fenil-5-oxoimidazolidina como inhibidores de proteasa de virus de inmunodeficiencia humana. | |
MX2020003760A (es) | Formulaciones de niraparib. | |
MX2020004255A (es) | Compuesto de pirimidina como inhibidor de las janocinasas. | |
MX2020003712A (es) | Union giratoria de pasaje multiple. | |
IL277472A (en) | Nucleic acid molecules for pseudouridylation | |
MX2020003706A (es) | Aminoimidazopiridazinas como inhibidores de cinasa. | |
MX2020004424A (es) | Formulacion aerosolizable. | |
MX2020004455A (es) | Derivados de pirrolopirazina como inhibidores de integrina alfa v. | |
ZA201906981B (en) | Stable multispecific antibodies | |
MX2018015697A (es) | Composición de alimentación que comprende una proteasa ácida. | |
MX2020007742A (es) | Procesos para preparar fluorocetolidos. | |
SG11202101258VA (en) | Immunoreactant carrier | |
MX2018004005A (es) | Ensayo de potencia celular. | |
MX2020004045A (es) | Molecula inhibidora del acido nucleico de la catenina beta. | |
EP3297991A4 (en) | Novel amidoheteroaryl aroyl hydrazide ethynes | |
IL283433A (en) | Small molecule inhibitors of ire1 | |
IL279419A (en) | CCL5 inhibitors |